PM
Prakash Maity
About Prakash Maity
Prakash Maity has 8 years in corporate governance. Holds Director role. Currently with 2 companies, including Abiocis Bio-Science Private Limited and Vapiano Laboratories Private Limited. Formerly with 2 companies, such as Lipleader Entercrop Private Limited and Glamatic Pharmaceuticals Private Limited. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Abiocis Bio-Science Private Limited
U24299TG2018PTC126179
|
Director | 14 Aug 2018 | 2018 | Active |
Vapiano Laboratories Private Limited
U85300OR2022PTC038759
|
Director | 27 Jan 2022 | 2022 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Lipleader Entercrop Private Limited
U51909AS2020PTC019960
|
Director | 16 Nov 2021 | 2020 | Active |
Glamatic Pharmaceuticals Private Limited
U24100WB2019PTC280474
|
Managing Director | 09 Oct 2019 | 2019 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Prakash Maity
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prakash Maity
Prakash Maity has 8 years in corporate governance. Holds Director role. Currently with 2 companies, including Abiocis Bio-Science Private Limited and Vapiano Laboratories Private Limited. Formerly with 2 companies, such as Lipleader Entercrop Private Limited and Glamatic Pharmaceuticals Private Limited. Engaged in General Business. Contributes to corporate operations.
Prakash Maity is associated with 2 companies as Director.
Prakash Maity has expertise in General Business.
Prakash Maity has 8 years in corporate governance.